Skip to main content

Join us at #SwissBiotechDay2023

๐Ÿ‘‹ Join us at #SwissBiotechDay2023 to learn about our breakthrough macrophage-based immunotherapy for the treatment of solid tumors. Our presentation, titled “Breakthrough Macrophage Based Immunotherapy For Treatment Of Solid Tumors,” will be held on โŒš April 24th at 16:15 โ€“ 16:30 in Room Rio, floor 2. Prof. Magdalena Krรณl, CEO of Cellis, will be the speaker.

As a clinical stage biotech company, Cellis is leading the way in the development of Macrophage Drug Conjugates (MDCs) – a new class of therapy for solid tumors. Using allogeneic macrophages conjugated with therapeutic medications, we’re focusing on the treatment of glioblastoma, ovarian, and pancreatic cancer. Our preclinical results show the elimination of tumors or significant tumor shrinkage, and we’re preparing to progress our technology to the first in human clinical trials.

Visit our website,, to learn more about our company profile and stay tuned for more updates from Swiss Biotech Day 2023! #technology #clinicaltrials #immunotherapy #macrophages